EUCTR2009-010834-23-BE进行中（未招募）1 期
A multi-center, double-masked study of the safety and efficacy of DuoTrav APS compared to DuoTrav in patients with open-angle glaucoma or ocular hypertension - Safety and Efficacy of DuoTrav APS versus DuoTrav
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients of either sex and any race ,of 18 years of age or older.
- •- Patients diagnosed with open-angle glaucoma (with or without pseudoexfoliation or
- •pigment dispersion component) or confirmed ocular hypertension who would benefit
- •from a fixed combination medication, in the opinion of the Investigator.
- •- Patients currently on a stable treatment (i.e., at least 30 days) with an IOP-lowering medication.
- •- Patients must meet the following IOP entry criteria in at least one eye at Eligibility
- •Visits 1 & 2:
- •Mean IOP = 24 mmHg at the 09:00 time point, and
- •Mean IOP = 21 mmHg at the 11:00 and 16:00 time points.
- •The mean IOP in either eye at Screening or Eligibility must not be greater than 36 mmHg at any time point.
- •The mean IOP is the average of IOP measurements in the same eye, as described in Section 9.4.7.
- •The same eye(s) must qualify at all qualifying time points.
- •- Only patients who satisfy all Informed Consent requirements may be included in the
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Pregnancy or females of childbearing potential not taking adeqaute birth control measures
- •- Any form of glaucoma other than open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or confirmed ocular hypertension
- •- Iridocorneal angle Shaffer grade < 2 (extreme narrow angle with complete or partial closure) in either eye, as measured by gonioscoy
- •- Cup/Disc ratio greater than 0.80 (horizontal or vertical) in either eye
- •- Severe central visual field loss in either eye
- •- History of, or current chronic, recurrent, or severe inflammatory eye disease (e.g.,
- •scleritis, uveitis, herpes keratitis), or current other severe ocular pathology (including
- •severe dry eye) that would affect the conduct of the study.
- •- History of ocular trauma within the past 6 months.
- •- Intraocular surgery within the past 6 months.
- •- Ocular laser surgery within the past 3 months.
- •- Best-corrected visual acuity score worse than 55 ETDRS letters (equivalent to
- •approximately 20/80 Snellen, 0.60 logMAR or 0.25 decimal)
- •- Current ocular infection or inflammation, or history of ocular infection or inflammation within the past 3 months as determined by patient history and/or eye examination.
- •- History of, or current clinically relevant (in the opinion of the Investigator) or
- •progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment.
- •- Any abnormality preventing reliable applanation tonometry.
- •- History of, or current evidence of severe illness or any other conditions which would
- •make the patient, in the opinion of the Investigator, unsuitable for the study.
- •- History of or current bronchial asthma, or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-adrenergic blocking agent.
- •- History of or current severe, unstable or uncontrolled cardiovascular, hepatic, or renal disease (e.g., sinus bradycardia, overt cardiac failure, greater than first degree
- •atrioventricular block, cardiogenic shock, clinically relevant angina or uncontrolled
- •hypertension) that would preclude the safe administration of a topical beta-adrenergic blocking agent.
- •- History of spontaneous or current hypoglycemia or uncontrolled diabetes.
- •- History of or current severe allergic rhinitis and bronchial hyper reactivity.
- •- History of or current corneal dystrophies.
- •- History of severe or serious hypersensitivity to prostaglandin drugs or their analogues, beta-adrenergic blocking agents, or to any components of the study medications.
- •- Patients who are unable, in the opinion of the Investigator, to safely discontinue use of all IOP-lowering medication(s) during the washout period.
- •- Less than 30 days stable dosing regimen before the Screening Visit of any medications or substances administered by any route and used on a chronic basis that may affect IOP, including, but not limited to, beta-adrenergic blocking agents.
- •Note: Patients must be on a stable dosing regimen of these medications for at least 30 days prior to the Screening Visit and must not change the dosing regimen during the eligibility period with the exception of a substitution of the patient’s current ocular hypotensive medication for one requiring a shorter washout period.
- •Note: Patients using non-prescription and/or prescription topical ophthalmic
- •medications that do not affect IOP may be included in the study.
- •- Use of any additional topical or systemic ocular hypotensive medication during the
- •- Patients wh
研究者
相似试验
进行中（未招募）
不适用
A multi-center, double-masked study of the safety and efficacy of Travoprost APS compared to TRAVATAN in patients with open-angle glaucoma or ocular hypertension. - Efficacy study of Travoprost APS versus TRAVATAEUCTR2008-006027-31-LVAlcon Research, Ltd.330
进行中（未招募）
不适用
A multi-center, double-masked study of the safety and efficacy of Travoprost APS compared to TRAVATAN in patients with open-angle glaucoma or ocular hypertension. - Efficacy study of Travoprost APS versus TRAVATAOpen-angle glaucoma or ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10030348Term: Open angle glaucomaMedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionEUCTR2008-006027-31-BEAlcon Research, Ltd.330
进行中（未招募）
1 期
A multi-center, double-masked study of the safety and efficacy of Travoprost APS compared to TRAVATAN in patients with open-angle glaucoma or ocular hypertension. - Efficacy study of Travoprost APS versus TRAVATAOpen-angle glaucoma or ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10030348Term: Open angle glaucomaMedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionEUCTR2008-006027-31-FRAlcon Research, Ltd.
已完成
3 期
A clinical trial to compare effect of Travoprost APS to TRAVATAN in patients with open-angle glaucoma or ocular hypertensioCTRI/2009/091/000528Alcon Research ltd330
进行中（未招募）
1 期
A Multi-Center, Double-Masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN® in Patients with Open-Angle Glaucoma or Ocular Hypertension - Safety and Efficacy of Travoprost APS versus TRAVATAN®EUCTR2008-002760-34-DEAlcon Research, Ltd.450